SUNRISE, Fla., Dec. 1, 2008 (GLOBE NEWSWIRE) -- Bioheart, Inc. (NasdaqCM:BHRT - News) announced today it has filed with appropriate agencies in Italy, Germany and the Netherlands for reimbursement approval for its MyoCell(r) myogenic cell therapy for heart failure. This patented composition and method has been studied in clinical trials involving more than 350 patients to date at over 100 centers worldwide since the year 2000. Data from one of these trials conducted by Bioheart indicates that about 84 percent of the myogenic stem cell treated patients improved in exercise capacity. In comparison, only 31 percent of the control patients on heart failure drugs improved.
